Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2017, Article ID 5846286, 5 pages
https://doi.org/10.1155/2017/5846286
Review Article

Myoinositol: The Bridge (PONTI) to Reach a Healthy Pregnancy

Clinical Genetics, ASST Cremona, Via Concordia 1, 26100 Cremona, Italy

Correspondence should be addressed to Pietro Cavalli; ti.anomerc.eladepso@illavac.p

Received 30 May 2016; Accepted 20 November 2016; Published 15 January 2017

Academic Editor: John E. Nestler

Copyright © 2017 Pietro Cavalli and Elena Ronda. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Dolk, M. Loane, and E. Garne, “The prevalence of congenital anomalies in Europe,” Advances in Experimental Medicine and Biology, vol. 686, pp. 349–364, 2010. View at Publisher · View at Google Scholar
  2. D. Stiefel, A. J. Copp, and M. Meuli, “Fetal spina bifida in a mouse model: loss of neural function in utero,” Journal of Neurosurgery, vol. 106, Supplement 3, pp. 213–221, 2007. View at Publisher · View at Google Scholar
  3. P. A. Boyd, C. Devigan, B. Khoshnood et al., “Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down’s syndrome,” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 115, no. 6, pp. 689–696, 2008. View at Publisher · View at Google Scholar
  4. C. Y. Johnson, M. A. Honein, W. Dana Flanders, P. P. Howards, G. P. Oakley Jr, and S. A. Rasmussen, “Pregnancy termination following prenatal diagnosis of anencephaly or spina bifida: a systematic review of the literature,” Birth Defects Research. Part A, Clinical and Molecular Teratology, vol. 94, no. 11, pp. 857–863, 2012. View at Publisher · View at Google Scholar
  5. L. M. De-Regil, A. C. Fernandez-Gaxiola, T. Dowswell, and J. P. Pena-Rosas, “Effects and safety of periconceptional folate supplementation for preventing birth defects,” Cochrane Database of Systematic Reviews, vol. 6, no. 10, Article ID CD007950, 2010. View at Publisher · View at Google Scholar
  6. H. Blencowe, S. Cousens, B. Modell, and J. Lawn, “Folic acid to reduce neonatal mortality from neural tube disorders,” International Journal of Epidemiology, vol. 39, Supplement 1, pp. i110–i120, 2010. View at Publisher · View at Google Scholar
  7. D. L. Cockroft, “Changes with gestational age in the nutritional requirements of postimplantation rat embryos in culture,” Teratology, vol. 45, no. 3, pp. 223–232, 1988. View at Publisher · View at Google Scholar
  8. L. Baker, R. Piddington, A. Goldman, J. Egler, and J. Moehring, “Myo-inositol and prostaglandins reverse the glucose inhibition of neural tube fusion in cultured mouse embryos,” Diabetologia, vol. 33, no. 10, pp. 593–596, 1990. View at Publisher · View at Google Scholar
  9. M. Hashimoto, S. Akazawa, M. Akazawa et al., “Effects of hyperglycaemia on sorbitol and myo-inositol contents of cultured embryos: treatment with aldose reductase inhibitor and myo-inositol supplementation,” Diabetologia, vol. 33, no. 10, pp. 597–602, 1990. View at Publisher · View at Google Scholar
  10. M. J. Seller, “Vitamins, folic acid and the cause and prevention of neural tube defects,” Ciba Foundation Symposium, vol. 181, pp. 161–173, 1994. View at Google Scholar
  11. M. Adinolfi, S. E. Beck, S. Embury, P. E. Polani, and M. J. Seller, “Levels of a-fetoprotein in amniotic fluid of mice (curly tail) with neural tube defects,” Journal of Medical Genetics, vol. 13, no. 6, pp. 511–513, 1976. View at Publisher · View at Google Scholar
  12. D. L. Cockroft, F. A. Brook, and A. J. Copp, “Inositol deficiency increases the susceptibility to neural tube defects of genetically predisposed (curly tail) mouse embryos in vitro,” Teratology, vol. 45, no. 2, pp. 223–232, 1992. View at Publisher · View at Google Scholar
  13. A. Fleming and A. J. Copp, “Embryonic folate metabolism and mouse neural tube defects,” Science, vol. 280, no. 5372, pp. 2107–2109, 1998. View at Publisher · View at Google Scholar
  14. A. J. Copp, “Relationship between timing of posterior neuropore closure and development of spinal neural tube defects in mutant (curly tail) and normal mouse embryos in culture,” Journal of Embryology and Experimental Morphology, vol. 88, no. 1, pp. 39–54, 1985. View at Google Scholar
  15. E. A. Reece, M. Khandelwal, Y. K. Wu, and M. Borenstein, “Dietary intake of myo-inositol and Neural tube defects in offspring of diabetic rats,” American Journal of Obstetrics and Gynecology, vol. 176, no. 3, pp. 536–539, 1997. View at Publisher · View at Google Scholar
  16. P. Cogram, A. Hynes, L. P. Dunlevy, N. D. Greene, and A. J. Copp, “Specific isoforms of proteine kinase C are essential for prevention of folate-resistant neural tube defects by inositol,” Human Molecular Genetics, vol. 13, no. 1, pp. 7–14, 2004. View at Publisher · View at Google Scholar
  17. M. P. Wilson, C. Hugge, M. Bielinska, P. Nicholas, P. W. Majerus, and D. B. Wilson, “Neural tube defects in mice with reduced levels of inositol 1,3,4-trisphosphate 5/6-kinase,” Proceedings National Academic Science US, vol. 106, no. 24, pp. 9831–9835, 2009. View at Publisher · View at Google Scholar
  18. P. W. Majerus, D. B. Wilson, C. Zhang, P. J. Nicholas, and M. P. Wilson, “Expression of inositol 1,3,4-trisphosphate 5/6-kinase (ITPK1) and its role in neural tube defects,” Advances in Enzyme Regulation, vol. 50, no. 1, pp. 365–372, 2010. View at Publisher · View at Google Scholar
  19. N. D. Greene and A. J. Copp, “Inositol prevents folate-resistant neural tube defects in the mouse,” Nature Medicine, vol. 3, no. 1, pp. 60–66, 1997. View at Publisher · View at Google Scholar
  20. P. M. Groenen, P. G. Peer, R. A. Wevers et al., “Maternal myo-inositol, glucose, and zinc status is associated with the risk of offspring with spina bifida,” American Journal of Obstetrics and Gynecology, vol. 189, no. 6, pp. 1713–1719, 2003. View at Publisher · View at Google Scholar
  21. P. Cavalli and A. J. Copp, “Inositol and folate resistant neural tube defects,” Journal of Medical Genetics, vol. 39, no. 2, pp. 2451–2458, 2002. View at Publisher · View at Google Scholar
  22. G. M. Shaw, S. L. Carmichael, W. Yang, and D. M. Schaffer, “Periconceptional dietary intake of myo-inositol and neural tube defects in offspring,” Birth Defects Research Part A, vol. 73, no. 3, pp. 184–187, 2005. View at Publisher · View at Google Scholar
  23. P. Cavalli, G. Tonni, E. Grosso, and C. Poggiani, “Effects of inositol supplementation in a cohort of mothers at risk of producing an NTD pregnancy,” Birth Defects Research. Part A, Clinical and Molecular Teratology, vol. 91, no. 11, pp. 962–965, 2011. View at Publisher · View at Google Scholar
  24. N. D. Greene, K. Y. Leung, V. Gay et al., “Inositol for the prevention of neural tube defects: a pilot randomised controlled trial,” The British Journal of Nutrition, vol. 115, no. 6, pp. 974–983, 2016. View at Publisher · View at Google Scholar
  25. P. Glasziou, I. Chalmers, M. Rawlins, and P. McCulloch, “When are randomised trials unnecessary? Picking signal from noise,” British Medical Journal, vol. 334, no. 7589, pp. 349–351, 2007. View at Publisher · View at Google Scholar